Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume: 76
Issue: 11
Year of Publication: 2023
Affiliated Institutions:
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Etablissement Français du Sang, La Plaine-St-Denis and Université de Franche-Comté, Besançon, France.
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Departments of Internal Medicine (Division of Infectious Diseases) and Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Department Transfusion Medicine, Division Blood Bank, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester campus, Minnesota, USA.
Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.
Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois, USA.
Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Department of Medicine, Infectious Diseases, Albert Einstein College of Medicine, Bronx, New York, USA.
Abstract summary
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.
Authors & Co-authors:
Bloch Evan M EM
Focosi Daniele D
Shoham Shmuel S
Senefeld Jonathon J
Tobian Aaron A R AAR
Baden Lindsey R LR
Tiberghien Pierre P
Sullivan David J DJ
Cohn Claudia C
Dioverti Veronica V
Henderson Jeffrey P JP
So-Osman Cynthia C
Juskewitch Justin E JE
Razonable Raymund R RR
Franchini Massimo M
Goel Ruchika R
Grossman Brenda J BJ
Casadevall Arturo A
Joyner Michael J MJ
Avery Robin K RK
Pirofski Liise-Anne LA
Gebo Kelly A KA
Study Outcome
Source Link: Visit source